Mid-Term Outcome after Extracorporeal Life Support in Postcardiotomy Cardiogenic Shock: Recovery and Quality of Life

• Published in: Journal of clinical medicine 2024-04, Vol.13 (8), p.2254
• Main Authors: Hanuna, Maja, Herz, German, Stanzl, Andre L, Li, Yupeng, Mueller, Christoph S, Kamla, Christine E, Scherer, Clemens, Wassilowsky, Dietmar, Juchem, Gerd, Orban, Martin, Peterss, Sven, Hagl, Christian, Joskowiak, Dominik
• Format: Article
• Language: English
• Subjects: Cardiac function; Cardiogenic shock; Care and treatment; Complications; Coronary artery bypass; Creatinine; Decision-making; Germany; Health aspects; Heart; Heart surgery; Hemodynamics; Hepatitis; Hospitals; Ischemia; Lactates; Life support systems (Critical care); Medical imaging; Mortality; Ostomy; Patient outcomes; Patients; Quality of life; Recovery (Medical); Regression analysis; Risk factors; Sepsis; Statistical analysis; Surgery; Survival analysis; Weaning
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm13082254

Extracorporeal life support (ECLS) therapy for refractory postcardiotomy cardiogenic shock (rPCS) is associated with high early mortality rates. This study aimed to identify negative predictors of mid-term survival and to assess health-related quality of life (HRQoL) and recovery of the survivors. Between 2017 and 2020, 142 consecutive patients received ECLS therapy following cardiac surgery. The median age was 66.0 [57.0-73.0] years, 67.6% were male and the median EuroSCORE II was 10.5% [4.2-21.3]. In 48 patients, HRQoL was examined using the 36-Item Short Form Survey (SF-36) and the modified Rankin-Scale (mRS) at a median follow-up time of 2.2 [1.9-3.2] years. Estimated survival rates at 3, 12, 24 and 36 months were 47%, 46%, 43% and 43% (SE: 4%). Multivariable Cox Proportional Hazard regression analysis revealed preoperative EuroSCORE II ( = 0.013), impaired renal function ( = 0.010), cardiopulmonary bypass duration ( = 0.015) and pre-ECLS lactate levels ( = 0.004) as independent predictors of mid-term mortality. At the time of follow-up, 83.3% of the survivors were free of moderate to severe disability (mRS < 3). SF-36 analysis showed a physical component summary of 45.5 ± 10.2 and a mental component summary of 50.6 ± 12.5. Considering the disease to be treated, ECLS for rPCS is associated with acceptable mid-term survival, health-related quality of life and functional status. Preoperative EuroSCORE II, impaired renal function, cardiopulmonary bypass duration and lactate levels prior to ECLS implantation were identified as negative predictors and should be included in the decision-making process.